Vanda Pharmaceuticals (NASDAQ:VNDA) Cut to Hold at Zacks Research

Zacks Research cut shares of Vanda Pharmaceuticals (NASDAQ:VNDA) from a strong-buy rating to a hold rating in a research note published on Wednesday morning,Zacks.com reports.

Other equities research analysts also recently issued research reports about the company. Cantor Fitzgerald restated an “overweight” rating on shares of Vanda Pharmaceuticals in a report on Wednesday, December 17th. UBS Group reissued a “buy” rating on shares of Vanda Pharmaceuticals in a research report on Monday, January 5th. B. Riley Financial upped their price objective on shares of Vanda Pharmaceuticals from $11.00 to $14.00 and gave the stock a “buy” rating in a report on Wednesday, December 31st. Jefferies Financial Group lifted their price objective on shares of Vanda Pharmaceuticals from $5.00 to $7.50 and gave the company a “hold” rating in a report on Wednesday, December 31st. Finally, HC Wainwright boosted their target price on shares of Vanda Pharmaceuticals from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, January 5th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $13.63.

Vanda Pharmaceuticals Stock Down 5.6%

Vanda Pharmaceuticals stock opened at $5.76 on Wednesday. The company has a market capitalization of $340.47 million, a PE ratio of -1.54 and a beta of 0.62. Vanda Pharmaceuticals has a 12-month low of $3.81 and a 12-month high of $9.60. The firm’s fifty day moving average is $7.32 and its 200 day moving average is $5.74. The company has a quick ratio of 2.38, a current ratio of 2.39 and a debt-to-equity ratio of 0.01.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) earnings per share for the quarter, missing the consensus estimate of ($2.18) by ($0.21). The company had revenue of $57.22 million for the quarter, compared to analyst estimates of $59.28 million. Vanda Pharmaceuticals had a negative net margin of 102.02% and a negative return on equity of 23.85%. As a group, sell-side analysts predict that Vanda Pharmaceuticals will post -1.12 EPS for the current fiscal year.

Institutional Trading of Vanda Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Mercer Global Advisors Inc. ADV grew its stake in Vanda Pharmaceuticals by 51.2% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 43,829 shares of the biopharmaceutical company’s stock valued at $387,000 after purchasing an additional 14,836 shares during the period. Susquehanna Portfolio Strategies LLC increased its holdings in Vanda Pharmaceuticals by 35.1% during the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 150,427 shares of the biopharmaceutical company’s stock worth $1,327,000 after buying an additional 39,087 shares during the last quarter. Balyasny Asset Management L.P. bought a new stake in Vanda Pharmaceuticals in the fourth quarter worth about $601,000. Schonfeld Strategic Advisors LLC purchased a new position in Vanda Pharmaceuticals in the fourth quarter valued at about $521,000. Finally, Jain Global LLC bought a new position in shares of Vanda Pharmaceuticals during the 4th quarter valued at approximately $94,000. 88.14% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Vanda Pharmaceuticals

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: Wall Street bullishness around the upcoming PDUFA for Bysanti — analysts and models show large upside if the FDA approves the bipolar/schizophrenia treatment, which is keeping speculative demand alive. FDA Calendar: Vanda Stock (VNDA) Shows 126% Upside with Bysanti Decision on Deck
• Positive Sentiment: Brokerage consensus remains above neutral — some coverage still labels VNDA a buy or “moderate buy,” supporting a baseline of institutional interest ahead of the regulatory decision. Vanda Pharmaceuticals Inc. Given Consensus Rating of “Moderate Buy” by Brokerages
• Neutral Sentiment: Trading was temporarily halted today for “VNDA” citing “News pending” — a pause that often precedes a material corporate or regulatory update and can amplify volatility when trading resumes.
• Neutral Sentiment: Widespread media attention: coverage and “buzz” ahead of the FDA verdict are driving elevated volume and short‑term momentum trading; that creates heightened risk/reward but not a clear directional signal until the decision. Vanda stock draws heavy buzz ahead of FDA verdict on Bysanti
• Neutral Sentiment: HC Wainwright maintains a Buy rating and a $22 price target but issued large downward revisions to near‑term EPS estimates — a mixed signal that keeps upside narratives alive while flagging weaker near‑term profitability. HC Wainwright analyst notes on Vanda
• Negative Sentiment: Zacks Research downgraded VNDA from “strong‑buy” to “hold,” signaling reduced conviction among some sell‑side analysts and likely contributing to downward pressure. Zacks Research downgrade
• Negative Sentiment: HC Wainwright sharply cut FY2026 and quarterly EPS forecasts (materially worsening loss projections), increasing concern about near‑term cash flow and execution if Bysanti or other catalysts don’t offset the shortfall. HC Wainwright EPS revisions
• Negative Sentiment: Analyst commentary framing VNDA as a “high‑risk” trade ahead of PDUFA emphasizes downside risk if the FDA rejects or requests more data — this narrative pressures risk‑averse investors and may amplify selling. Vanda Pharma: High Risk, Heavily Discounted – Stock Ahead Of PDUFA This Week

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.